Just in case folks hadn't seen this . . .
>>CHESHIRE, Conn., Dec. 5 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals (Nasdaq: ALXN - News) will conduct a conference call to review the results of its clinical trial of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) as presented at the American Society of Hematology Meeting.
Monday, December 9, 2002
12:30 p.m. Eastern
To participate in this call,
dial: 719-457-2633
confirmation code: 508793
shortly before 12:30 p.m. Eastern
To reserve a line,
please call Rhonda Chiger at Rx Communications Group, LLC
917-322-2569.
A replay of the call will be available from 3:30 p.m. Eastern through midnight Monday, December 16th, 2002. The replay number is 719-457-0820, confirmation code 508793.
As previously announced, results of the Phase I pilot study of eculizumab in PNH patients will be presented at the 44th Annual American Society of Hematology (ASH) Meeting in Philadelphia on December 9th at 8:45am. The presentation will be made by Dr. Peter Hillmen, MB, ChB, PhD, Consultant Hematologist of The General Infirmary at Leeds, Leeds, United Kingdom. Alexion expects to issue a press release to coincide with the start of Dr. Hillmen's presentation.<<
snip
Cheers, Tuck |
